Characteristics of patients and transplants
| . | CsA-MTX (N = 50) . | PTCy (N = 57) . | P . |
|---|---|---|---|
| Age, median (range), y | 49 (16-65) | 51 (18-67) | .877 |
| Male sex, n (%) | 34 (68) | 37 (65) | .737 |
| Diagnosis, n (%) | .402 | ||
| AML and MDS | 25 (50) | 26 (46) | |
| ALL | 11 (22) | 10 (18) | |
| NHL and CLL | 9 (18) | 11 (18) | |
| Others | 5 (10) | 10 (18) | |
| Disease risk index, n (%) | .356 | ||
| Low | 2 (4) | 3 (5) | |
| Intermediate | 35 (70) | 43 (75) | |
| High/very high | 13 (26) | 11 (20) | |
| Pretransplant status, n (%) | .602 | ||
| Complete response | 31 (62) | 36 (63) | |
| Partial response or active disease | 19 (38) | 21 (37) | |
| Donor/recipient sex, female/male, n (%) | 15 (30) | 17 (30) | .984 |
| Stem cell source, n (%) | .077 | ||
| BM | 2 (4) | 8 (14) | |
| Peripheral blood | 48 (96) | 49 (86) | |
| Graft composition, median (range) | |||
| CD34+, ×106/kg | 5.2 (4-6) | 4.4 (3-6.5) | .057 |
| TNC, ×108/kg | 9.5 (7-12) | 7.4 (5-11) | .108 |
| Conditioning regimen, n (%) | .015 | ||
| Reduced intensity | 18 (36) | 34 (60) | |
| FluMel | 11 (61) | 4 (12) | |
| Bu-Flu | 6 (33) | 6 (18) | |
| TBF-RIC | 0 (0) | 21 (65) | |
| Myeloablative | 32 (64) | 23 (40) | |
| Bu-Flu | 27 (84) | 11 (48) | |
| TBI-Cy | 4 (13) | 0 (0) | |
| TBF-MAC | 0 (0) | 12 (52) | |
| GVHD prophylaxis, n (%) | — | ||
| PTCY +3, +5, and CsA day 0 | 0 (0) | 38 (65) | — |
| PTCy +3, +4, and CsA + MMF day 5 | 0 (0) | 19 (35) | — |
| CsA day −1 and MTX +1, +3, +6 | 22 (44) | 0 (0) | — |
| CsA day −1 and MTX +1, +3, +6, +11 | 28 (56) | 0 (0) | — |
| . | CsA-MTX (N = 50) . | PTCy (N = 57) . | P . |
|---|---|---|---|
| Age, median (range), y | 49 (16-65) | 51 (18-67) | .877 |
| Male sex, n (%) | 34 (68) | 37 (65) | .737 |
| Diagnosis, n (%) | .402 | ||
| AML and MDS | 25 (50) | 26 (46) | |
| ALL | 11 (22) | 10 (18) | |
| NHL and CLL | 9 (18) | 11 (18) | |
| Others | 5 (10) | 10 (18) | |
| Disease risk index, n (%) | .356 | ||
| Low | 2 (4) | 3 (5) | |
| Intermediate | 35 (70) | 43 (75) | |
| High/very high | 13 (26) | 11 (20) | |
| Pretransplant status, n (%) | .602 | ||
| Complete response | 31 (62) | 36 (63) | |
| Partial response or active disease | 19 (38) | 21 (37) | |
| Donor/recipient sex, female/male, n (%) | 15 (30) | 17 (30) | .984 |
| Stem cell source, n (%) | .077 | ||
| BM | 2 (4) | 8 (14) | |
| Peripheral blood | 48 (96) | 49 (86) | |
| Graft composition, median (range) | |||
| CD34+, ×106/kg | 5.2 (4-6) | 4.4 (3-6.5) | .057 |
| TNC, ×108/kg | 9.5 (7-12) | 7.4 (5-11) | .108 |
| Conditioning regimen, n (%) | .015 | ||
| Reduced intensity | 18 (36) | 34 (60) | |
| FluMel | 11 (61) | 4 (12) | |
| Bu-Flu | 6 (33) | 6 (18) | |
| TBF-RIC | 0 (0) | 21 (65) | |
| Myeloablative | 32 (64) | 23 (40) | |
| Bu-Flu | 27 (84) | 11 (48) | |
| TBI-Cy | 4 (13) | 0 (0) | |
| TBF-MAC | 0 (0) | 12 (52) | |
| GVHD prophylaxis, n (%) | — | ||
| PTCY +3, +5, and CsA day 0 | 0 (0) | 38 (65) | — |
| PTCy +3, +4, and CsA + MMF day 5 | 0 (0) | 19 (35) | — |
| CsA day −1 and MTX +1, +3, +6 | 22 (44) | 0 (0) | — |
| CsA day −1 and MTX +1, +3, +6, +11 | 28 (56) | 0 (0) | — |
ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CLL, chronic lymphatic leukemia; MDS, myelodysplastic syndrome; Mel, melphalan; NHL, non-Hodgkin lymphoma; TBI, total body irradiation; TNC, total nucleated cell count.